Aldosterone antagonists and outcomes in real-world older patients with heart failure and preserved ejection fraction

JACC: Heart Failure

Volumn 1, Issue 1, 2013, Pages 40-47

  Patel, Kanan ^a   Fonarow, Gregg C ^b   Kitzman, Dalane W ^c   Aban, Inmaculada B ^a   Love, Thomas E ^d   Allman, Richard M ^a,e   Gheorghiade, Mihai ^f   Ahmed, Ali ^a,e  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WAKE FOREST UNIVERSITY   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e BIRMINGHAM VA MEDICAL CENTER   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Aldosterone antagonists; Heart failure; Preserved ejection fraction

Indexed keywords

ALDOSTERONE ANTAGONIST; MINERALOCORTICOID ANTAGONIST;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; COHORT ANALYSIS; HEART FAILURE; HEART STROKE VOLUME; HOSPITAL DISCHARGE; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VERY ELDERLY;

AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HEART FAILURE; HUMANS; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PATIENT DISCHARGE; STROKE VOLUME; TREATMENT OUTCOME;

EID: 84875513232     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2012.08.001     Document Type: Article

References (42)

1. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
2. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
3. Zannad F., McMurray J.J., Krum H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011, 364:11-21.
4. Ahmed A., Perry G.J., Fleg J.L., Love T.E., Goff D.C., Kitzman D.W. Outcomes in ambulatory chronic systolic and diastolic heart failure: a propensity score analysis. Am Heart J 2006, 152:956-966.
5. Fonarow G.C., Stough W.G., Abraham W.T., et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007, 50:768-777.
6. Zannad F. Aldosterone and heart failure. Eur Heart J 1995, 16(Suppl N):98-102.
7. Deswal A., Richardson P., Bozkurt B., Mann D.L. Results of the Randomized Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction Trial (RAAM-PEF). J Card Fail 2011, 17:634-642.
8. Mak G.J., Ledwidge M.T., Watson C.J., et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol 2009, 54:1674-1682.
9. Desai A.S., Lewis E.F., Li R., et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J 2011, 162:966-972.e10.
10. D'Agostino R.B., D'Agostino R.B. Estimating treatment effects using observational data. JAMA 2007, 297:314-316.
11. Michels K.B., Braunwald E. Estimating treatment effects from observational data: dissonant and resonant notes from the SYMPHONY trials. JAMA 2002, 287:3130-3132.
12. Masoudi F.A., Havranek E.P., Wolfe P., et al. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J 2003, 146:250-257.
13. Zhang Y., Kilgore M.L., Arora T., et al. Design and rationale of studies of neurohormonal blockade and outcomes in diastolic heart failure using OPTIMIZE-HF registry linked to Medicare data. Int J Cardiol 2011 Nov 24, [E-pub ahead of print].
14. Fonarow G.C., Abraham W.T., Albert N.M., et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J 2004, 148:43-51.
15. Fonarow G.C., Abraham W.T., Albert N.M., et al. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA 2007, 297:61-70.
16. Gheorghiade M., Abraham W.T., Albert N.M., et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006, 296:2217-2226.
17. Hunt S.A., Abraham W.T., Chin M.H., et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009, 53:e1-90.
18. Dickstein K., Cohen-Solal A., Filippatos G., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008, 29:2388-2442.
19. Danaei G., Tavakkoli M., Hernan M.A. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol 2012, 175:250-262.
20. Hernan M.A., Hernandez-Diaz S., Robins J.M. A structural approach to selection bias. Epidemiology 2004, 15:615-625.
21. Ray W.A. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003, 158:915-920.
22. Rosenbaum P.R., Rubin D.B. The central role of propensity score in observational studies for causal effects. Biometrika 1983, 70:41-55.
23. Rubin D.B. Using propensity score to help design observational studies: application to the tobacco litigation. Health Serv Outcome Res Methodol 2001, 2:169-188.
24. Austin P.C. Primer on statistical interpretation or methods report card on propensity-score matching in the cardiology literature from 2004 to 2006: a systematic review. Circ Cardiovasc Qual Outcomes 2008, 1:62-67.
25. Ahmed A., Husain A., Love T.E., et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 2006, 27:1431-1439.
26. Ahmed A., Rich M.W., Love T.E., et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006, 27:178-186.
27. Ahmed M.I., White M., Ekundayo O.J., et al. A history of atrial fibrillation and outcomes in chronic advanced systolic heart failure: a propensity-matched study. Eur Heart J 2009, 30:2029-2037.
28. Bowling C.B., Pitt B., Ahmed M.I., et al. Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail 2010, 3:253-260.
29. Roy B., Desai R.V., Mujib M., et al. Effect of warfarin on outcomes in septuagenarian patients with atrial fibrillation. Am J Cardiol 2012, 109:370-377.
30. Filippatos G.S., Ahmed M.I., Gladden J.D., et al. Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: potential mechanistic insights from epidemiological data. Eur Heart J 2011, 32:712-720.
31. Deedwania P.C., Ahmed M.I., Feller M.A., et al. Impact of diabetes mellitus on outcomes in patients with acute myocardial infarction and systolic heart failure. Eur J Heart Fail 2011, 13:551-559.
32. Curtis L.H., Greiner M.A., Hammill B.G., et al. Representativeness of a national heart failure quality-of-care registry: comparison of OPTIMIZE-HF and non-OPTIMIZE-HF Medicare patients. Circ Cardiovasc Qual Outcomes 2009, 2:377-384.
33. Rosenbaum P.R. Sensitivity to hidden bias. Observational Studies 2002, 105-170. Springer-Verlag, New York, NY. P.R. Rosenbaum (Ed.).
34. Kitzman D.W., Little W.C., Brubaker P.H., et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002, 288:2144-2150.
35. Feller M.A., Mujib M., Zhang Y., et al. Baseline characteristics, quality of care, and outcomes of younger and older Medicare beneficiaries hospitalized with heart failure: findings from the Alabama Heart Failure Project. Int J Cardiol 2011, 162:39-44.
36. Cleland J.G., Tendera M., Adamus J., Freemantle N., Polonski L., Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006, 27:2338-2345.
37. Massie B.M., Carson P.E., McMurray J.J., et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008, 359:2456-2467.
38. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777-781.
39. Zile M.R., Gaasch W.H., Anand I.S., et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation 2010, 121:1393-1405.
40. Clarke R., Shipley M., Lewington S., et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol 1999, 150:341-353.
41. Butler J., Arbogast P.G., Daugherty J., Jain M.K., Ray W.A., Griffin M.R. Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. J Am Coll Cardiol 2004, 43:2036-2043.
42. Ezekowitz J.A., Lee D.S., Tu J.V., Newman A.M., McAlister F.A. Comparison of one-year outcome (death and rehospitalization) in hospitalized heart failure patients with left ventricular ejection fraction >50% versus those with ejection fraction <50%. Am J Cardiol 2008, 102:79-83.